IRIS Accounts Production v24.3.0.553 11169075 Board of Directors Board of Directors 1.4.23 31.3.24 31.3.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh111690752023-03-31111690752024-03-31111690752023-04-012024-03-31111690752022-03-31111690752022-04-012023-03-31111690752023-03-3111169075ns15:EnglandWales2023-04-012024-03-3111169075ns14:PoundSterling2023-04-012024-03-3111169075ns10:Director12023-04-012024-03-3111169075ns10:Director22023-04-012024-03-3111169075ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3111169075ns10:SmallEntities2023-04-012024-03-3111169075ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3111169075ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3111169075ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3111169075ns10:FullAccounts2023-04-012024-03-3111169075ns10:RegisteredOffice2023-04-012024-03-3111169075ns5:CurrentFinancialInstruments2024-03-3111169075ns5:CurrentFinancialInstruments2023-03-3111169075ns5:ShareCapital2024-03-3111169075ns5:ShareCapital2023-03-3111169075ns5:RetainedEarningsAccumulatedLosses2024-03-3111169075ns5:RetainedEarningsAccumulatedLosses2023-03-3111169075ns5:PlantMachinery2023-04-012024-03-3111169075ns5:PlantMachinery2023-03-3111169075ns5:PlantMachinery2024-03-3111169075ns5:PlantMachinery2023-03-3111169075ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3111169075ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-31
REGISTERED NUMBER: 11169075 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 March 2024

for

Synergy Medicine Limited

Synergy Medicine Limited (Registered number: 11169075)






Contents of the Financial Statements
for the Year Ended 31 March 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Synergy Medicine Limited

Company Information
for the Year Ended 31 March 2024







DIRECTORS: Dr M Al-Dawoud
Dr J A Johnston





REGISTERED OFFICE: Suite 12 Jason House
Kerry Hill
Horsforth
Leeds
West Yorkshire
LS18 4JR





REGISTERED NUMBER: 11169075 (England and Wales)





ACCOUNTANTS: Yorkshire Medical Accountants LLP
Suite 12
East Wing, Jason House
Kerry Hill, Horsforth
Leeds
West Yorkshire
LS18 4JR

Synergy Medicine Limited (Registered number: 11169075)

Balance Sheet
31 March 2024

31.3.24 31.3.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 55,286 4,756

CURRENT ASSETS
Debtors 5 4,721 3,064
Cash at bank and in hand 136,136 280,511
140,857 283,575
CREDITORS
Amounts falling due within one year 6 3,106 45,838
NET CURRENT ASSETS 137,751 237,737
TOTAL ASSETS LESS CURRENT
LIABILITIES

193,037

242,493

PROVISIONS FOR LIABILITIES 10,505 903
NET ASSETS 182,532 241,590

CAPITAL AND RESERVES
Called up share capital 120 120
Retained earnings 182,412 241,470
182,532 241,590

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Synergy Medicine Limited (Registered number: 11169075)

Balance Sheet - continued
31 March 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 21 October 2024 and were signed on its behalf by:




Dr M Al-Dawoud - Director



Dr J A Johnston - Director


Synergy Medicine Limited (Registered number: 11169075)

Notes to the Financial Statements
for the Year Ended 31 March 2024

1. STATUTORY INFORMATION

Synergy Medicine Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance, 15% on reducing balance and Straight line over 3 years

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

Synergy Medicine Limited (Registered number: 11169075)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 April 2023 5,971
Additions 56,019
At 31 March 2024 61,990
DEPRECIATION
At 1 April 2023 1,215
Charge for year 5,489
At 31 March 2024 6,704
NET BOOK VALUE
At 31 March 2024 55,286
At 31 March 2023 4,756

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade debtors - 870
Other debtors 4,721 2,194
4,721 3,064

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade creditors 24 144
Taxation and social security 109 24,479
Other creditors 2,973 21,215
3,106 45,838

7. RELATED PARTY DISCLOSURES

During the year, total dividends of £90,477 (2023 - £71,500) were paid to the directors .

Included in other creditors at the year end are amounts owing to the directors of £4 (2023 - £18,272).